Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Raltegravir may cause hair loss in some patients.

This study reported that among 10 tested 2-(4-chlorophenyl)-5-aryl-1,3,4-oxadiazole compounds, compound 4c showed the highest activity against cancer cell lines, with a 95.37% average growth rate.

Male hormones affect COVID-19 severity and certain drugs targeting these hormones could help reduce the risk.

This study reports that Elvitegravir, a drug currently approved for other uses, shows potential as a neuro- and mitoprotective agent by attenuating mitochondrial damage caused by NMDA receptors in primary mouse cortical neurons.

This study consisted of a pharmacy master's thesis detailing practical experiences during a hospital and community pharmacy internship and scientific investigations into the off-label use of dutasteride for androgenetic alopecia and oral vaccines for urinary tract infection prophylaxis, emphasizing therapeutic applications and mechanisms of action.

This article discusses vaccination coverage for BCG, Polio, and Hepatitis B in Juiz de Fora using SUS data and reports no new results; the authors aim to hypothesize reasons for coverage variation.

This report describes the first case of hair loss in a patient on ritonavir-boosted atazanavir therapy for HIV, with hair regrowth following a switch to a non-protease inhibitor regimen.

This study reported that COVID-19 patients treated with nirmatrelvir/ritonavir had lower anti-spike IgG levels and different cytokine patterns compared to those not receiving antiviral treatment, suggesting early antiviral use may alter immune response by reducing viral load and antigen presentation.

This review reports that nirmatrelvir-ritonavir has significant drug-drug interactions with many common dermatological medications, whereas molnupiravir may be an alternative therapy due to the absence of such interactions observed so far.

This study observed that patients undergoing indinavir/ritonavir therapy for HIV-1 frequently experienced reversible alopecia, likely due to retinoid-like effects, but these were independent of other retinoid-like skin manifestations.

This report describes a case of alopecia totalis associated with lopinavir/ritonavir in an HIV-positive patient, which reversed after discontinuation of the drug.

This study found that finasteride significantly inhibits the metabolism of tirilazad to its active metabolites without greatly affecting tirilazad's overall clearance.

This review discusses the role of mitochondria and evaluates methodologies for assessing mitochondrial function and toxicity, particularly in the context of HIV and antiretroviral treatments, but it reports no new empirical findings.

This observational study suggests that antiretroviral drugs that interact with CYP 3A4 enzymes may alter finasteride's effectiveness for hair loss in men treated for HIV.

This case report documents a woman with HIV who developed severe hair loss after starting lopinavir-ritonavir, which improved upon switching to a different antiretroviral drug.

This study found that tenofovir alafenamide fumarate (TAF) is an effective and safer alternative to tenofovir disoproxil fumarate (TDF) for chronic hepatitis B, with fewer long-term side effects like nephrotoxicity and decreased bone density.

In this case report, researchers highlight a 57-year-old HIV patient on ritonavir who developed Cushing’s syndrome from over-the-counter intranasal fluticasone, underscoring the risks of drug interactions and the importance of counseling patients about potential steroid ingredients in OTC products.

This study found that coadministration of tadalafil and finasteride improved lower urinary tract symptoms and erectile function in men with benign prostatic hyperplasia better than finasteride alone over 26 weeks.

This study reports that using 5-alpha reductase inhibitors is associated with a 31% increased risk of depression, highlighting that the choice of comparator group significantly affects study results.

This study discusses levetiracetam's role as an alternative treatment for idiopathic generalized epilepsies, highlighting its potential effectiveness, especially for patients unsuitable for valproate.

In this study, ALRV5XR significantly increased hair regrowth in women with androgenetic alopecia or telogen effluvium, with no adverse events reported.

In this study, sustained-release sodium valproate showed high efficacy in achieving seizure remission for adults with focal and generalized epilepsy over one year, but side effects like weight gain and tremor were more frequent among heterozygous carriers of certain gene variants.

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

This study identified common and unexpected adverse events associated with ritlecitinib in real-world use, providing insights into its safety profile for treating severe alopecia areata.

This study evaluated the long-term safety of ritlecitinib in adolescents with alopecia areata and found it to be well-tolerated without new safety concerns over approximately five years, with common adverse events including positive SARS-CoV-2 tests, acne, headache, and nasopharyngitis.

This meta-analysis reports that 5-alpha-reductase inhibitors are associated with a 31% increased risk of depression, with varying outcomes depending on the comparator group, highlighting significant heterogeneity across studies.

This compilation lists potential side effects, drug interactions, and trade names of various dermatological and antiretroviral medications, but it reports no original research findings.

This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.

In this study, ritlecitinib was generally well tolerated in pediatric alopecia areata patients aged 6 to <12 years, with no severe or serious adverse events reported, and the drug's pharmacokinetic parameters were successfully characterized.